Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: BRAF V600E-mutant Metastatic Colorectal Cancer Clear all

Active, not recruiting Phase 3 Interventional

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421

View directory record Official record

Conditions: Neoplasms
Interventions: Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, Capecitabine, Bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older

Enrollment: 831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 62
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 38 more

Source: ClinicalTrials.gov public record

Updated Aug 13, 2025 · Synced May 21, 2026, 10:21 PM EDT

Active, not recruiting Phase 2 Interventional

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446

View directory record Official record

Conditions: Metastatic Colorectal Cancer
Interventions: Encorafenib, Cetuximab, Pembrolizumab; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older

Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Miami Beach, Florida + 2 more

Source: ClinicalTrials.gov public record

Updated Apr 6, 2026 · Synced May 21, 2026, 10:21 PM EDT

Completed Phase 2 Interventional Results available

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

NCT03693170

View directory record Official record

Conditions: BRAF V600E-mutant Metastatic Colorectal Cancer
Interventions: encorafenib, Binimetinib, Cetuximab; Drug
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: 18 Years and older

Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: New York, New York • Germantown, Tennessee

Source: ClinicalTrials.gov public record

Updated Feb 1, 2024 · Synced May 21, 2026, 10:21 PM EDT

Completed Phase 3 Interventional Results available

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

NCT02928224

View directory record Official record

Conditions: BRAF V600E-mutant Metastatic Colorectal Cancer
Interventions: Encorafenib, Binimetinib, Cetuximab, Irinotecan, Folinic Acid, 5-Fluorouracil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 90
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 45 more

Source: ClinicalTrials.gov public record

Updated Dec 20, 2023 · Synced May 21, 2026, 10:21 PM EDT